Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly

被引：179

作者：

Bevan, JS ^{[1
]}

机构：

[1] Aberdeen Royal Infirm, Dept Endocrinol, Aberdeen AB25 2ZN, Scotland

来源：

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM | 2005年 / 90卷 / 03期

关键词：

D O I：

10.1210/jc.2004-1093

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Somatostatin analogs are the mainstay of medical therapy for acromegaly. Suppression of GH hypersecretion, lowering of IGF-I production, and control of symptoms are established benefits of therapy. In addition, clinically significant tumor shrinkage has been seen in a number of studies, particularly in patients undergoing primary medical therapy. This review summarizes current knowledge of the effects of somatostatin analogs on tumor size and cellular morphology and examines the available data on predictors of tumor shrinkage.

引用

页码：1856 / 1863

页数：8

共 77 条

[1] Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre [J].

Abe, T ;

Lüdecke, DK .

EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2001, 145 (02) :137-145

[2] Long-term effects of lanreotide SR and octreotide LAR® on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly [J].

Amato, G ;

Mazziotti, G ;

Rotondi, M ;

Iorio, S ;

Doga, M ;

Sorvillo, F ;

Manganella, G ;

Di Salle, F ;

Giustina, A ;

Carella, C .

CLINICAL ENDOCRINOLOGY, 2002, 56 (01) :65-71

[3]

Anthony LB, 1999, ITAL J GASTROENTEROL, V31, pS216

[4] EFFECTS OF TREATMENT WITH OCTREOTIDE IN ACROMEGALIC PATIENTS - A MULTICENTER ITALIAN STUDY [J].

AROSIO, M ;

MACCHELLI, S ;

ROSSI, CM ;

CASATI, G ;

BIELLA, O ;

FAGLIA, G ;

MARTINO, E ;

SQUATRITO, S ;

GIUSTI, M ;

CANNAVO, S ;

VELARDO, A ;

SICOLO, N ;

BARBARINO, A ;

TAMBURRANO, G ;

CICCARELLI, E .

EUROPEAN JOURNAL OF ENDOCRINOLOGY, 1995, 133 (04) :430-439

[5] GH/IGF-I normalization and tumor shrinkage during long-term treatment of acromegaly by lanreotide [J].

Attanasio, R ;

Barausse, M ;

Cozzi, R .

JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2001, 24 (04) :209-216

[6] Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg) [J].

Baldelli, R ;

Colao, A ;

Razzore, P ;

Jaffrain-Rea, ML ;

Marzullo, P ;

Ciccarelli, E ;

Ferretti, E ;

Ferone, D ;

Gaia, D ;

Camanni, F ;

Lombardi, G ;

Tamburrano, G .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (11) :4099-4103

[7] TREATMENT OF ACROMEGALY WITH THE LONG-ACTING SOMATOSTATIN ANALOG SMS-201-995 [J].

BARKAN, AL ;

KELCH, RP ;

HOPWOOD, NJ ;

BEITINS, IZ .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1988, 66 (01) :16-23

[8] PREOPERATIVE TREATMENT OF ACROMEGALY WITH LONG-ACTING SOMATOSTATIN ANALOG SMS-201-995 - SHRINKAGE OF INVASIVE PITUITARY MACROADENOMAS AND IMPROVED SURGICAL REMISSION RATE [J].

BARKAN, AL ;

LLOYD, RV ;

CHANDLER, WF ;

HATFIELD, MK ;

GEBARSKI, SS ;

KELCH, RP ;

BEITINS, IZ .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1988, 67 (05) :1040-1048

[9] OCTREOTIDE - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC POTENTIAL IN CONDITIONS ASSOCIATED WITH EXCESSIVE PEPTIDE SECRETION [J].

BATTERSHILL, PE ;

CLISSOLD, SP .

DRUGS, 1989, 38 (05) :658-702

[10] Somatostatin receptors [J].

Benali, N ;

Ferjoux, G ;

Puente, E ;

Buscail, L ;

Susini, C .

DIGESTION, 2000, 62 :27-32

← 1 2 3 4 5 6 7 8 →